3D MEDICINES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.22 HKD | +0.97% |
|
+11.87% | -18.59% |
| Mar. 29 | 3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12% | MT |
| Mar. 28 | 3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
3D Medicines Biotechnology Shanghai Co Ltd is a China-based company mainly engaged in the research and development of commercial tumor products and candidate drugs. The Company's main product pipelines including an immuno-oncology monotherapy, drug candidates with mechanisms of action amenable to combination within the pipeline, and pain management assets. The Company's core product is subcutaneous injection of anti-PD-L1, envafolimab. The Company also has a number of candidate drugs in clinical stage, including peptide cancer vaccine 3D189, GAS6 decoy receptor 3D229, fibroblast growth factor receptor (FGFR) 3D185 and others. The Company mainly conducts its business in the domestic market.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.59% | 180M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 1244 Stock
- News 3D Medicines Inc.
- SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines
